Page last updated: 2024-08-26

fulvestrant and 4-hydroxy-n-desmethyltamoxifen

fulvestrant has been researched along with 4-hydroxy-n-desmethyltamoxifen in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Ceron, CS; Desta, Z; Flockhart, DA; Montenegro, MF; Salgado, MC; Tanus-Santos, JE	1
Hui, Y; Kurogi, K; Liu, MC; Luo, L; Sakakibara, Y; Suiko, M; Zhang, L; Zhou, C	1
Adjei, AA; Ames, MM; Black, J; Buhrow, SA; Chalmers, ZR; Collins, JM; Dockter, T; Doroshow, JH; Erlichman, C; Frampton, G; Goetz, MP; Haddad, T; Hawse, JR; Ingle, JN; Kipp, BR; Kuffel, M; Liu, MC; Mahr, MA; McGovern, RM; Northfelt, DW; Ralya, AT; Reid, JM; Safgren, SL; Streicher, H; Suman, VJ; Visscher, D	1
Bruinsma, ES; Emch, MJ; Goetz, MP; Hawse, JR; Ingle, JN; Jones, CJ; Subramaniam, M	1

Trials

1 trial(s) available for fulvestrant and 4-hydroxy-n-desmethyltamoxifen

Article	Year
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-20, Volume: 35, Issue:30 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytochrome P-450 CYP2D6; Disease-Free Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Tamoxifen	2017

Article

Year

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-20, Volume: 35, Issue:30

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytochrome P-450 CYP2D6; Disease-Free Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Tamoxifen

2017

Other Studies

3 other study(ies) available for fulvestrant and 4-hydroxy-n-desmethyltamoxifen

Article	Year
Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:6 Topics: Animals; Antineoplastic Agents, Hormonal; Aorta, Thoracic; Estradiol; Fulvestrant; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Prostaglandins; Rats; Rats, Wistar; Tamoxifen; Vasodilation	2011
Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis. Journal of pharmacological sciences, 2015, Volume: 128, Issue:3 Topics: Catalysis; Cytosol; Estradiol; Fulvestrant; Hep G2 Cells; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Sulfates; Sulfotransferases; Tamoxifen	2015
Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models. Molecular cancer research : MCR, 2021, Volume: 19, Issue:6 Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Models, Biological; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen	2021